chinabiotoday.com
Industry Insights - ChinaBio® Today
http://www.chinabiotoday.com/categories/insights
Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. China Investment 2015: Rasing the Bar. Legal and IP Issues. Raquo; Industry Insights. Science and business issues impacting the China biotech industry. China Ranks #1 in Survey of Asian Biopharma Clusters. May 31, 2016. Share this with colleagues:. May 13, 2016.
chinabiotoday.com
WuXi PharmaTech Receives $3.2 Billion Privatization Offer - ChinaBio® Today
http://www.chinabiotoday.com/articles/20150430
Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. China Investment 2015: Rasing the Bar. Legal and IP Issues. Raquo; Deals and Financings. Raquo; WuXi PharmaTech Receives $3.2 Billion Privatization Offer. WuXi PharmaTech Receives $3.2 Billion Privatization Offer. Publication date: Apr 30, 2015. Click here to join.
chinabiotoday.com
Education Center - ChinaBio® Today
http://www.chinabiotoday.com/categories/edu
Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. China Investment 2015: Rasing the Bar. Legal and IP Issues. Raquo; Education Center. Greg Scott Interviewed at BIO-Europe Spring. China Investment 2014 n. China Partnering 2013 n. China Investment 2013 n. China Partnering 2012 n. Download China Life Sience 2012.
chinabiotoday.com
Guizhou Xinbang Pharma Buys Hangzhou Chinese Peptide for $323 Million - ChinaBio® Today
http://www.chinabiotoday.com/articles/20150506_1
Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. China Investment 2015: Rasing the Bar. Legal and IP Issues. Raquo; Deals and Financings. Raquo; Guizhou Xinbang Pharma Buys Hangzhou Chinese Peptide for $323 Million. Guizhou Xinbang Pharma Buys Hangzhou Chinese Peptide for $323 Million. Click here to join.
chinabio.live.subhub.com
In My Opinion - ChinaBio® Today
http://chinabio.live.subhub.com/categories/inmyopinion
Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. China Investment 2015: Rasing the Bar. Legal and IP Issues. Raquo; In My Opinion. China View: JP Morgan Healthcare Conference, 2013. Jan 10, 2013. The annual pilgrimage to. Rsquo;s 22% market growth, JPMorgan is a must-attend event. More details. Jan 16, 2011.
SOCIAL ENGAGEMENT